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Abstract
Doxorubicin is one of the most potent anticancer drugs used in the treatment of various can-
cer types. The efficacy of doxorubicin is influenced by the drug resistance mechanisms
and its cytotoxicity. In this study, we performed a high-copy screening analysis to find genes
that play a role in doxorubicin resistance and found several genes (CUE5, AKL1, CAN1,
YHR177W and PDR5) that provide resistance. Among these genes, overexpression of
PDR5 provided a remarkable resistance, and deletion of it significantly rendered the toler-
ance level for the drug. Q-PCR analyses suggested that transcriptional regulation of these
genes was not dependent on doxorubicin treatment. Additionally, we profiled the global
expression pattern of cells in response to doxorubicin treatment and highlighted the genes
and pathways that are important in doxorubicin tolerance/toxicity. Our results suggest that
many efflux pumps and DNAmetabolism genes are upregulated by the drug and required
for doxorubicin tolerance.
Introduction
Doxorubicin is an anthracycline with a strong anticancer activity. It exerts its effects through
different mechanisms, such as intercalation into DNA and inhibition of DNA/RNA biosynthe-
sis, formation of free radicals, inhibition of topoisomerase II, changing membrane properties
and inhibition of RNA helicase [1,2]. Unfortunately, these different modes of actions for doxo-
rubicin bring along serious side effects. The most notable one is its cardiotoxicity [3]. Doxoru-
bicin leads to iron accumulation and ROS production, which eventually damages
mitochondria and leads to cardiac problems [4].
Multi-drug resistance (MDR) is believed to be an important cause of the treatment failure in
metastatic cancer patients [5]. The efflux of the chemotherapeutics by membrane transporters
is the main mechanism leading to MDR. Even though mechanisms of MDR have not been
revealed exclusively, evading drug resistance and controlling MDR, have been a great issue in
chemotherapy.
The mechanisms of doxorubicin resistance have been studied both in yeast and mammalian
cells. In mammals, resistance mechanisms include primarily drug efflux from the cell via
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upregulation of the P-glycoprotein [6], multidrug resistance protein (MRP) [7], anthracycline
resistance associated protein MRP6 [8], breast cancer resistance protein (BCRP) [9], and lung
resistance-related protein (LRP) [10]. Additionally, changes in the topoisomerase II expression
[11], overexpression of glutathione S-transferase (GST) [12], and changes in ERK1/ERK2 pro-
teins [13] provide resistance to doxorubicin.
The budding yeast S. cerevisiae is a valuable model to identify doxorubicin resistance and
sensitivity genes. Screening of deletion collection strains for non-essential genes and studies
with specific genes have revealed many genes and pathways in doxorubicin tolerance in yeast
[14,15]. These include Ssl2 protein [16], Bsd2 protein [17], SUMO pathway [18], nascent poly-
peptide-associated complex activity in ribosomes [19], extracellular signal-regulated kinases
ERK1 and ERK2 [13], endocytic Ark/Prk kinase [20], nitrogen permease regulator 2 (Npr2)
[21], cytochrome oxidase subunit IV gene [22], and overexpression of CLN1, CLN2 and ERG13
[23]. Additionally, checkpoint and recombination functions in G1 and early S phase [14], as
well as several proteins involved in DNA repair, RNA metabolism, chromatin remodeling,
amino acid metabolism, and heat shock response [15], play roles in doxorubicin resistance.
Identification of new genes that play role in cancer drug resistance may provide further
prognostic information, which in turn may help to improve the development of new chemo-
therapeutic agents and increase efficacy of chemotherapeutics. In this study, we intended to
identify doxorubicin resistance mechanisms by performing a high copy genomic DNA library
screening in the presence of doxorubicin. Several new genes were found to cause resistance
against high level of doxorubicin (500μM). Among these genes, PDR5 had the most remarkable
effect on doxorubicin resistance. We also profiled the expression pattern of yeast genome for
doxorubicin treatment and highlighted the paths that played roles in resistance and detoxifica-
tion for this drug.
Materials and Methods
Yeast strains, cell growth and plasmids
The BY4741 (MATa, his3Δ1 leu2Δ0 met15Δ0 ura3Δ0) and BY4743 (MATa, his3Δ1/his3Δ1
leu2Δ0/leu2Δ0 LYS2/lys2Δ0 met15Δ0/MET15 ura3Δ0/ura3Δ0) strains of the budding yeast Sac-
charomyces cerevisiae were used in this study. The high copy yeast genomic library (ATCC No.
37323) was used for genomic library screenings. Yeast transformations were performed by the
standard LiAc method. Unless indicated otherwise, all experiments were performed on Yeast
Nitrogen Base (YNB, 2% Glucose) media supplemented with appropriate amino acids and
bases.
For yeast expression experiments, the genes that reside within the original YEp13 genomic
clones that caused resistance against Doxorubicin, were each cloned separately into the
pAG426-GPD plasmid (Addgene) and then expressed under control of the GPD promoter,
except for PDR5 plasmid, which was obtained from Prof. Dr. Wenjun Guan (Zhejiang Univer-
sity, China). For plasmid isolations, yeast cells were predigested by lyticase (5u/ml) for 30 min-
utes in Tris-EDTA (TE) buffer before the isolation and plasmids were isolated from yeast cells
by using GeneJET Plasmid Miniprep kit (Thermo-Molecular Biology) as described by the man-
ufacturer. The isolated plasmids were amplified in E. coli DH5α cells and sequenced by using a
pair of vector-specific primers at IzTech Biotechnology Center (Izmir). Doxorubicin was pur-
chased from SABA pharmaceuticals (Cat No.: 8699511796063 /Turkey).
Gradient spot assays
Petri plates with a continuous gradient of a drug was described by Szybalski and Bryson
(1952). Briefly, two layers of agar were poured into a square petri dish. The bottom layer
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contained normal medium and the plate was propped up slightly for agar to cover the entire bot-
tom.When the agar was solidified, the dish was placed in a horizontal position and doxorubicin
harbouring medium (50 ml) was added on top of the plate. Downward diffusion of doxorubicin
resulted in its dilution proportional to the thickness of the agar layers and established a concen-
tration gradient changing from approximately 0 μM on one side to 500 μM on the other [24].
The WT BY4741 and BY4743 strains carrying the plasmids were grown overnight diluted
by growth media and incubated 3h to obtain exponentially growing cells. Cells were washed
with dH2O, diluted to OD600 0.02 and 5 μl of cell solution was transferred to each spot. Plates
were photographed after three days of incubation at 30°C.
RNA isolation and real-time PCR analysis
Total RNA samples from exponentially growing yeast cells were isolated using the RNeasy
Mini Kit (Qiagen). Genomic DNA contaminations were removed by DNase treatment (Dnase
RQ1, Promega). cDNA synthesis was performed using the First Strand cDNA Synthesis Kit
(Fermentas) according to the manufacturer’s instructions. The cDNAs were used as templates
to amplify internal parts of the selected genes. ACT1 gene was used as an internal control. Real-
time PCR assays were performed with IQ5 real-time PCR system (BIO-RAD).
Microarray analysis
Concentrations and purity of RNA samples were determined by measuring their absorbances
at 260/280nm, using a nanodrop spectrophotometer (Thermo Scientific), and the quality of
RNAs were determined by Agilent RNA 6000 Nano Kit in Agilent Bioanalyzer.
Total RNA and spike-in mixes were prepared by mixing minimum 100ng of total RNA and
spike-in kit for each qualified RNA sample. Total RNA sample was resuspended in nuclease-
free water to obtain minimum of 50ng/μl RNA. The spike-in solution and T7 primer mix was
added on diluted RNA samples and denaturation was performed by incubating the mix at 65°C
for 10 minutes. cDNA master mix was prepared and added on each RNA sample mix. The mix
was then incubated at 40°C for 2 hours; 70°C for 10 minutes and on ice for 5 minutes, respec-
tively. The Cyanine-3-labeled and amplified RNA samples (cRNA) were purified and quantifi-
cation was performed by using Nanodrop spectrophotometer (Thermo Scientific).
For hybridization, cRNA samples were incubated with a fragmentation buffer and gene
expression blocking agent at 60°C for 30 minutes. The fragmented samples were loaded on
arrays and the array slides were placed in a hybridization oven and the hybridization reaction
was performed at 65°C for 18 hours. After the hybridization step, the samples were washed
with a washing solution. The washing step was performed at room temperature for the first
and the second washes. The third wash was performed at 37°C. After the washing step, the
slides were scanned and signal intensities were obtained by a feature extraction program.
Statistical analysis
Student’s T-test was used for Real-time PCR analysis and fold-change analysis was used for
microarray analysis data. P–value 0.05 was chosen as the significance level (p< 0.05) for statis-
tical analysis.
Results and Discussion
Screening for the genes that show resistance to doxorubicin
In order to identify genes that confer resistance to doxorubicin, we first determined the toxic
drug concentrations for our strains. We analyzed cell growth rates in different drug
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concentrations in liquid media for both haploid (BY4741) and diploid (BY4743) wild type
cells. As seen in Fig 1, the growth of both strains was completely inhibited in the presence of
200 μM or higher amounts of doxorubicin. Next, we transformed wild type (BY4741) cells with
a 2μ-based genomic expression library and isolated 6 transformants that could grow in the
presence of 500 μM of doxorubicin on solid media. By using a high concentration of doxorubi-
cin for screening, we aimed to find genes that help cells tolerate very toxic levels of the drug.
Plasmids from the transformants were isolated and amplified in E. coli and used for the re-
Fig 1. Growth curves.Wild type (A) haploid and (B) diploid yeast strains on 0 μM, 100 μM, 200 μM and 300 μM doxorubicin media. Error bars represent SD
of the means for triplicate determinations.
doi:10.1371/journal.pone.0145108.g001
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transformation of fresh wild type cells for confirmation purposes. All the isolated plasmids
conferred resistance to the new cells, thus, we confirmed that the resistance observed in the
original transformants were provided by the plasmids.
The nucleotide sequences of the expression cassettes in each plasmid were determined.
Sequence analyses yielded nine intact genes (Table 1). In order to find out which one of these
genes provided resistance, they were all cloned onto the pAG426-GDP plasmid individually
and expressed in haploid (BY4741) and diploid (BY4743) wild type cells. As seen in Fig 2A and
2B, only expression of AKL1, CUE5, CAN1, YHR177w and PDR5 genes provided resistance to
doxorubicin. Particularly, cells overexpressing PDR5 gene were highly resistant to the drug and
able to grow in the presence of 2 mM of doxorubicin (Fig 2C), which is the highest dose that
could be tolerated by yeast cells as of our knowledge.
As the next step, we analyzed the deletion mutants of AKL1, CUE5, CAN1, YHR177w and
PDR5 genes in both haploid and diploid backgrounds to identify whether they were sensitive to
doxorubicin (Fig 3A and 3B). In both backgrounds, pdr5Δmutants were the most sensitive
cells and their growth was inhibited by 50 μM of doxorubicin. In addition to pdr5Δmutants,
akl1Δ cells were also more sensitive to doxorubicin when compared to wild type cells, however
the rest of the mutants (cue5Δ, can1Δ and yhr177wΔ) showed a growth pattern similar to that
of wild type cells.
Pdr5p is a member of the ATP-binding cassette family of transporters and mediates resis-
tance to many xenobiotics such as mutagens, antifungals and steroids [25,26]. In addition to
drug stress, it is also involved in cation resistance [27], and lipid transport in yeast cells [28].
Pdr5 resembles (orthologous) mammalian MDR1 which is a major factor in tumor resistance
[29]. Regulation of PDR5 is controlled by transcription factors PDR1 and PDR3 and deletion of
these transcription factors leads to loss of PDR5 expression, while gain of function mutations
in pdr1/3 leads to over expression of this protein [30–32].
Being an efflux pump, PDR5 gene has previously shown to be associated with doxorubicin
resistance. Golin et. al. showed that pdr5Δmutants could not grow at 50μM doxorubicin [33]
and Rogers et. al. showed that pdr5Δmutants are sensitive to doxorubicin [34]. Kolaczkowski
et al (1996) showed that pdr1-3mutants, that overexpress PDR5, are doxorubicin resistant,
while the pdr5Δmutant is sensitive to the drug [35]. A more recent study has shown that pdr1-
3mutation leads to upregulation of about twenty-five other genes in addition to PDR5 [36],
which may also affect the resistance level in pdr1-3mutants. Here, we showed that not only
pdr5Δmutants were doxorubucin sensitive but also PDR5 overexpression from a plasmid
increased doxorubicin resistance, which supports the findings from previous studies [33–35].
PDR5, SNQ2 and YOR1 are known to be major determinants of multidrug resistance in
yeast and they all are controlled by PDR1 [30,37,38]. In order to check if PDR5 overexpression
may lead to resistance to doxorubucin in the absence of these genes, we overexpressed PDR5 in
yor1Δ, snq2Δ and pdr1Δmutants and analyzed them by a spotting assay (Fig 4). In addition to
doxorubicin, transformants were also tested on clatrimazole, an inhibitor of ergosterol synthe-
sis in fungi [39], and cerulenin, an inhibitor of fatty acid synthesis [40], since both are known
Table 1. Genomic sequences that were responsible for doxorubicin resistance.
Colony No Chromosome Information Covered Genes
1 Chromosome XV Coordinates 407059 bp to 411911 bp GLO4, CUE5, part of WHI2
2 Chromosome V Coordinates 30280 bp to 33605 bp CAN1
3 Chromosome II Coordinates 346000 bp to 366000 TSC3, AKL1
4 Chromosome VII Coordinates 445000 bp to 465000 bp YHR177w
5 Chromosome XV Coordinates 607000 bp to 627000 bp YOR152C, PDR5
doi:10.1371/journal.pone.0145108.t001
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to be substrates of Pdr5 (S1 Fig). PDR5 overexpression made these cells resistant to all three
drugs. The pdr1Δ strain was more sensitive to the drugs compared to the wild type cells,
whereas snq2Δ and yor1Δmutants showed no sensitivity. Cerulenin was very toxic to cells and
only cells that carried PDR5 plasmid were able to survive in the presence of this drug even at
the minimal concentrations (S1 Fig). We also noticed that PDR5 overexpressing pdr1Δ cells
were less resistant to the drugs compared to PDR5 overexpressing wild type cells. On the other
hand, yor1Δmutants were previously shown to be sensitive to doxorubicin [34], however we
did not observe this phenotype under our experimental conditions.
Another gene whose overexpression provided resistance and deletion rendered cells to
doxorubicin was AKL1. Akl1, which is a serine-threonine protein kinase involved in endocyto-
sis and actin cytoskeleton organization [41], has previously been linked to doxorubicin resis-
tance by others [14]. Sla1/Pan1/End3 complex is involved in endocytosis and affected by Akl1
Fig 2. Spotting assays for overexpression analyses.Candidate genes that play role in doxorubicin
resistance were cloned into pAG426-GPD plasmid and expressed in (A) haploid and (B) diploid wild type
strains in the presence of doxorubucin. (C)Overexpression of the PDR5 gene could provide resistance to 2
mM of doxorubucin.
doi:10.1371/journal.pone.0145108.g002
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overexpression [20]. Akl1 phosphorylates Pan1p and leads to dissociation of the yeast Sla1/
Pan1/End3 complex, which regulates the internalization step of endocytosis [42]. Dissociation
Fig 3. Spotting assays for sensitivity analyses. (A) Haploid and (B) diploid deletion mutants of the
candidate genes were analyzed by a spotting assay for their doxorubicin sensitivity. Serial dilutions (5 μl)
(OD600 0.2, 0.02, 0.002 and 0.0002) for each strain were used for the sensitivity analyses.
doi:10.1371/journal.pone.0145108.g003
Fig 4. PDR5 overexpression analyses in yor1Δ, snq2Δ and pdr1Δmutants. PDR5 gene was overexpressed in wild type, yor1Δ, snq2Δ, pdr1Δ, and
pdr5Δ cells and growth rates were determined by a spotting assay in the presence of doxorubicin gradient.
doi:10.1371/journal.pone.0145108.g004
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of the complex subsequently results in inhibition of endocytosis. Reduction in endocytosis did
not affect doxorubicin accumulation significantly [20], and only very few drugs have been shown
to enter cells through endocytosis [29]. Therefore, resistance to doxorubicin provided by Akl1p
overexpression may be through mechanisms other than reduced endocytosis. However, reduc-
tion in endocytosis may have indirect effects on doxorubucin resistance, because end4 endocyto-
sis mutants accumulate Pdr5p at the plasma membrane [35,43]. To test if doxorubicin resistance
in AKL1 overexpressing strain is somehow affected by the presence of Pdr5, we overexpressed
AKL1 in pdr5Δmutants and spotted cells in the presence of doxorubicin (Fig 5) and other drugs
(S2 Fig). Our results indicated that AKL1 overexpression in pdr5Δmutants did not make cells
resistant to doxorubicin or to other drugs, which suggested that PDR5 was required for Akl1
action. It is likely that AKL1 overexpression may act through Pdr5 stabilization in plasma mem-
brane. Overexpression of AAK1, which is the human orthologue of AKL1, also causes doxorubi-
cin resistance in Hela cells [20], suggesting that the role of AKL1 in doxorubicin resistance is
conserved in higher eukaryotes, but the mechanisms of resistance are not clear yet.
CAN1, YHR177W and CUE5 are the other genes obtained from genomic library screening,
of which their overexpression made cells resistance to doxorubicin, but their deletion mutants
did not show any sensitivity. Can1p is a plasma membrane arginine permease, arginine-H+
symporter, which is exclusively associated with lipid rafts [44]. Possible doxorubicin resistance
mechanism for CAN1may be upregulation of filamentous growth due to its location in ergos-
terol-rich domains of the plasma membrane that harbors several proteins required for filamen-
tous growth [45].
YHR177w is a putative transcription factor with a WOPR domain, of which its overexpres-
sion causes either cell cycle delay or arrest [46]. Proteins with WOPR domains are important
in pathogenesis [46] and YHR177w overexpression leads to invasive growth (pseudohyphae
formation) in yeast [47]. Therefore, YHR177w overexpression may also cause doxorubicin
resistance through activation of invasive growth.
Cue5p functions as ubiquitin-Atg8p adaptor in ubiquitin-dependent autophagy [48,49] and
it is role in drug resistance is not clear.
Expression patterns of resistance genes in response to doxorubicin
treatment
Screening analyses showed that the overexpression of PDR5, AKL1, CAN1, YHR177W and
CUE5 from a plasmid provided doxorubicin resistance, however it is not known whether these
Fig 5. AKL1 overexpression analyses in pdr5Δmutants. AKL1was overexpressed in haploid pdr5Δmutants and doxorubicin resistance was tested by a
spotting assay.
doi:10.1371/journal.pone.0145108.g005
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genes are upregulated or not in the presence of doxorubicin. In order to study expression pat-
terns of these genes, we incubated cells with a sublethal dose of doxorubicin (80 μM) for two
hours and determined the transcript levels of each gene by a Real-Time PCR approach (Fig 6).
Interestingly, expression of only AKL1 increased slightly (1.5-fold) (p = 0,25) and the rest of
the genes did not physiologically respond to the drug. Expression analyses also showed that
PDR1, a known activator of PDR5, expression was not activated by doxorubicin treatment.
Thus, these genes were not transcriptionally responsive to doxorubicin and provided resistance
only if they were expressed ectopically. On the other hand, doxorubicin sensitivity of pdr5Δ
and akl1Δmutants suggested a possible role for these genes in doxorubicin resistance with
their basal expression levels.
Global expression profiling for doxorubicin response
To further evaluate the mechanisms of doxorubicin resistance and toxicity, we analyzed the
changes in the global gene expression profile of yeast cells after doxorubicin exposure.
The genes showing more than 2-fold changes (p<0.05) are listed in S1 Table. Our microar-
ray results also showed that doxorubicin resistance genes were not upregulated in response to
the drug treatment and were consistent with the qPCR data. Out of approximately 6200 yeast
genes, 211 of them were significantly upregulated, while 148 genes were downregulated. We
categorized these genes by functional MIPS classification (Tables 2 and 3) to highlight the path-
ways that play role in doxorubicin tolerance and toxicity.
Funspec analysis [50] of the upregulated genes showed that paths related to transport
dependent-detoxification systems and DNA metabolism such as DNA restriction, integration
and recombination were upregulated in the presence of doxorubicin (Table 2).
Among the transporters (Table 2) polyamine transporter TPO2, azole resistance gene
AZR1, drug:H(+) antiporter YHK8, pleotropic drug resistance gene PDR18 and membrane
Fig 6. Real-Time PCR analyses of the genes that cause resistance to doxorubicin. The expression levels for genes were normalized by their untreated
counterparts. Each sample was assayed at least 3 times and error bars show the SD of the means. ACT1 gene was used as the internal control.
doi:10.1371/journal.pone.0145108.g006
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proteins Pnt1 and Svs1 were upregulated in response to doxorubicin. Pdr18, besides being a
membrane transporter, can affect the membrane sterol composition and lead to MDR pheno-
type [51]. Among the upregulated genesMRE1 (meiotic recombination) andMMS4 (Methyl
Methane Sulfonate Sensitivity) both function in DNA repair [52,53], and are related to doxoru-
bicin sensitivity [15,54].
When we functionally categorized the down-regulated genes in response to doxorubicin
treatment, only a small fraction of genes were clustered (Table 3).
Mainly, expression of iron transporters (FIT1, FIT2 and FIT3), sugar transporters (HXT15,
HXT13,HXT16 and HXT17) and proton driven antiporters (KHA1 and ATO2) were inhibited
by doxorubicin.
Yeast responds to iron limitations by activating Aft1 transcription factor and expressing
FIT1, FIT2 and FIT3 genes. These genes encode for mannoproteins that are incorporated into
the cell wall and play roles in retention of siderophore-iron in the cell wall [55]. Decreasing
iron levels by inhibition of FIT1, FIT2 and FIT3 genes might be a good defense system for
doxorubicin toxicity, since iron plays role in doxorubicin cytotoxicity by producing ROS [4].
Sugar transporters that were downregulated by doxorubicin are all low affinity hexose trans-
porters and their roles in drug response is not known.
Ion transporters KHA1 and ATO2 play role as K(+)/H(+) antiporter and ammonia extruder,
respectively [56,57]. Inhibition of KHA1may lead to accumulation of K(+) and disruption of
vacuole membrane potential, which might be important in doxorubicin transport/defense.
However, resistance to doxorubicin decreases in kha1Δmutants [54]. Thus, the exact role of
KHA1 in doxorubicin resistance is not clear. Similarly, possible benefits that could be gained by
lowering the transcript levels of ATO2, ammonia transporter, are not clear.
Our microarray and real-time PCR results were consistent with each other. They both con-
firmed that none of the genes obtained from genomic library screenings were upregulated by
doxorubicin treatment. The genomic DNA library used in this work was a high copy number
(2 μ) library and supposedly genes on the plasmids were expressed at high levels. We observed
that PDR5mRNA level was 7-fold higher than that of empty vector carrying transformants (S3
Fig) (p = 0,039) and that was apparently enough for cells to tolerate 2mM doxorubicin.
Seemingly, doxorubicin did not activate the transcriptional machinery required for the
expression of PDR5, CAN1, YHR177W and CUE5 genes since their mRNA levels did not
change much upon the treatment. A specific support for the transcriptional inertness of these
genes was the unaffected level of PDR1, an activator of PDR5 gene (Fig 6). In addition to Pdr1,
transcription factors Pdr3, Yap1, and Mig3 also play roles in expression of PDR5 in response to
Table 2. MIPS functional classification of >2-fold upregulated genes in response to Doxorubicin treatment (p value cutoff: 0.01).
Category p-value In Category from Cluster k f
DNA restriction [10.01.09.03] 1.865e-05 AI1 AI2 AI4 MMS4 MRE11 5 12
detoxification [32.07] 0.003305 ADH5 FZF1 TPO2 AZR1 YHK8 PDR18 PNT1 SVS1 8 80
meiosis I [10.03.02.01] 0.006791 REC104 MRE11 NDJ1 3 13
DNA integration [10.01.05.03.05] 0.009102 AI1 AI4 2 5
doi:10.1371/journal.pone.0145108.t002
Table 3. MIPS functional classification of >2-fold downregulated genes in response to Doxorubicin treatment (p value cutoff: 0.01).
Category p-value In Category from Cluster k f
ion transport [20.01.01] 0.0003473 FIT1 FIT2 FIT3 3 7
sugar transport [20.01.03.01] 0.004537 HXT15 HXT13 HXT16 HXT17 4 31
proton driven antiporter [20.03.02.03.01] 0.00948 KHA1 ATO2 2 7
doi:10.1371/journal.pone.0145108.t003
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drug/chemical stress exposure [58], however, their mRNA levels were not increased signifi-
cantly by the doxorubicin treatment (S1 Table). Thus, even though PDR5 played a major role
in doxorubicin tolerance, the transcription factors that regulate it were not activated by doxo-
rubicin treatment.
Conclusion
In this study, we screened a yeast genomic DNA library to identify genes that are responsible
for doxorubicin resistance and found that PDR5 was the primary gene that played role in doxo-
rubicin tolerance. Our screen also pointed out roles of other genes such as, AKL1, CAN1,
YHR177W and CUE5 in protecting cells from doxorubicin toxicity. We also showed that tran-
scriptional regulation of these genes was not dependent on doxorubicin treatment, however,
overexpression of them make S. cerevisiae cells resistant to high doses of doxorubicin.
Additionally, we analyzed the global expression profile of yeast cells after doxorubicin treat-
ment and highlighted the genes and paths that might be important in doxorubicin tolerance
and toxicity. Our results showed that membrane transporters
and DNA metabolism genes are upregulated in the presence of doxorubicin and these genes
may function in doxorubicin detoxification/tolerance processes.
When we consider the genes whose overexpression caused doxorubicin resistance, exclud-
ing Cue5, their common effect seemed to be the change in membrane asymmetry. Thus, chang-
ing the composition of the cell membrane could be a common response of cells to high
doxorubicin levels.
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S1 Fig. Spotting assays for PDR5 overexpression. PDR5 was cloned and expressed in wild
type, yor1Δ, snq2Δ, pdr1Δ, and pdr5Δ cells. Spotting assays were performed on (A) clatrimazole
and (B) cerulenin.
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S2 Fig. Spotting assays for AKL1 overexpression. AKL1 was cloned and expressed in akl1Δ
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S3 Fig. Real-time PCR analyses for PDR5 overexpression. PDR5 transcript analyses in hap-
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